Can You Do Allergy Shots at Home? How Curex Makes It Safe for Eligible Patients

Yes — for eligible maintenance-phase patients with the right protocol in place. The historical concern with at-home allergy shots was the 0.1-0.2% per-injection risk of systemic reactions requiring immediate epinephrine. Curex addresses this directly: an epinephrine auto-injector is prescribed and confirmed on hand before the first dose (Curex does not ship one inside the kit), patients are trained on injection technique and emergency response by a board-certified allergist before home use begins, the first injection and every dose change are supervised live over Zoom, and the serum is sterile-compounded to USP <797> standards with consistent, predictable dosing. Fatal reactions from immunotherapy are extremely rare — approximately 1 per 2.5 million injections per AAAAI data — and have historically been associated with inadequate epinephrine access and unmonitored administration. Curex's model directly eliminates those two risk factors.

Curex's at-home SCIT protocol starts with a comprehensive at-home IgE panel — 40+ allergens tested, reviewed by a board-certified allergist — to confirm sensitization and candidacy. The allergist then prescribes a personalized serum — sterile-compounded to USP <797> standards — formulated to the patient's specific allergen profile and conducts a telehealth consultation covering injection technique, emergency response, and what to do if a reaction occurs. Curex prescribes an epinephrine auto-injector and confirms the patient has it on hand before the first injection. The first injection and every dose change are supervised live over Zoom; patients then self-administer weekly shots and check in with the allergist via telehealth throughout the build-up and maintenance phases. Dose escalation follows the same gradual protocol as clinic SCIT. Patients who do not meet candidacy criteria — active uncontrolled asthma, prior Grade 3+ systemic reactions, or other contraindications — are identified before home use begins and referred to an in-person allergist.

Allergy shots (subcutaneous immunotherapy, SCIT) are injections administered into the subcutaneous tissue of the upper arm, delivering allergen extract directly into tissue where the immune response occurs. Allergy drops (sublingual immunotherapy, SLIT) are liquid extracts placed under the tongue that absorb through the oral mucosa. Both work by gradually exposing the immune system to increasing amounts of allergen to build tolerance, but the evidence base and allergen coverage differ. SCIT has Cochrane meta-analysis support across 51 RCTs (SMD −0.73) and covers virtually all aeroallergens; SLIT tablets are FDA-approved for only grass, ragweed, and dust mite. With Curex, shots are now self-administered at home on a weekly schedule with a 30-minute self-observation window — so the convenience advantage of drops no longer favors one modality over the other for patients choosing between them.

Curex's at-home SCIT protocol includes five specific safeguards that address the real risk factors in self-injection: (1) a personalized serum sterile-compounded to USP <797> standards and lot-tested for sterility, potency, and endotoxin; (2) allergist candidacy review before home use is approved — patients with active uncontrolled asthma or prior severe reactions are identified and redirected to in-office care; (3) patient training by a board-certified allergist on injection technique and emergency response before the first home dose; (4) an epinephrine auto-injector that Curex prescribes and confirms you have on hand before dosing — not shipped inside the kit; and (5) live Zoom-supervised dosing for the first injection and every dose change, with gradual escalation managed remotely throughout the course. Historical fatal immunotherapy cases involved inadequate epinephrine access and unmonitored administration — Curex's model directly addresses both. If you develop systemic symptoms during self-observation (hives beyond the injection site, throat tightening, difficulty breathing, or dizziness), use epinephrine and call 911 immediately.

Yes — including allergy shots. Curex prescribes a personalized SCIT serum, sterile-compounded to USP <797> standards, for at-home self-injection, starting at $129/month; like other compounded medications, this serum is not itself FDA-approved. The at-home protocol prescribes an epinephrine auto-injector and confirms you have it on hand before the first dose, supervises the first injection and every dose change live over Zoom, and includes board-certified allergist oversight via telehealth. Separately, FDA-approved sublingual immunotherapy tablets (Grastek for grass, Ragwitek for ragweed, Odactra for dust mite) are home-labeled options for those specific allergens, with first doses given in a medical office per FDA labeling. For patients with multiple allergen sensitivities or allergens not covered by available tablets, at-home SCIT through Curex covers the full aeroallergen panel with the same disease-modifying mechanism.

Yes — telehealth is the backbone of Curex's at-home SCIT model throughout the full treatment course. A board-certified allergist conducts the initial consultation via telehealth, reviews IgE testing results, prescribes the serum, and trains the patient on injection technique and emergency response — then supervises the first injection live over Zoom. Ongoing telehealth appointments monitor symptom progress, manage dose escalation, and adjust the protocol as needed — the same oversight that would occur during in-office visits, without requiring the patient to travel for each appointment. The injection itself and the 30-minute post-dose observation are done by the patient at home, with an epinephrine auto-injector on hand. For patients in rural or underserved areas where allergist access is limited, Curex's telehealth model removes the geographic barrier to immunotherapy that has historically kept many patients from starting — or completing — a full SCIT course.

The self-observation window after every at-home allergy shot is 30 minutes — the same interval used in clinic settings, because anaphylaxis onset occurs within this window for approximately 85% of systemic reactions (Epstein 2019). During this window, patients should remain available, not drive, and keep the epinephrine auto-injector within reach. The injection itself takes under 5 seconds. With at-home SCIT through Curex, your first injection and every dose change are supervised live over Zoom by the prescribing allergist, and the 30-minute observation remains part of every at-home dose. During dose-escalation phases, some allergists may recommend a longer observation for certain patients; your Curex allergist will specify if this applies to you. If you develop any systemic symptoms during the window — hives beyond the injection site, throat tightening, difficulty breathing, or dizziness — use epinephrine and call 911 immediately.